William Blair analyst Sami Corwin has reiterated their bullish stance on NGNE stock, giving a Buy rating yesterday.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sami Corwin has given his Buy rating due to a combination of factors related to Neurogene’s promising therapeutic candidate, NGN-401, for the treatment of Rett syndrome. The recent investor lunch with Neurogene’s leadership highlighted the broad and durable clinical benefits observed in the Phase I/II study of NGN-401, which positions it as a potentially best-in-class therapy for Rett syndrome.
The pivotal Embolden trial’s primary endpoint, which involves achieving a CGI-I score of ≤3 and gaining at least one developmental skill, is seen as de-risked due to the favorable response rate required for success. Furthermore, the achievement of secondary endpoints, such as a CGI-I score of ≤2 and the gain of multiple developmental skills, is expected to provide deeper insights into the therapy’s benefits and enhance its competitive positioning. The use of multiple clinical trial sites and independent raters is anticipated to enhance data integrity, further supporting the positive outlook for NGN-401’s commercial adoption.